Tyrosine kinase inhibitors (TKIs) are an effective treatment strategy for non-small cell lung
cancer (NSCLC) patients harboring mutations that result in constitutive activation of the …

Efficacy of EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, to treat human
non-small cell lung cancers (NSCLCs) with activating mutations in EGFR is not persistent …

Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an
irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR …

Background Identification of tumor dependencies is important for developing therapeutic
strategies for liver cancer. Methods A genome-wide CRISPR screen was performed for …

Background: Osimertinib-based therapy effectively improves the prognosis of lung
adenocarcinoma (LUAD) patients with epidermal growth factor receptor mutations. However …

Therapeutic benefits offered by tyrosine kinase inhibitors (TKIs), such as gefitinib (Iressa)
and erlotinib (Tarceva), are limited due to the development of resistance, which contributes …

Lung cancer is the leading cause of cancer mortality worldwide. The treatment of patients
with lung cancer harboring mutant EGFR with orally administered EGFR tyrosine kinase …

MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory
clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative …

Compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is
associated with relatively poor outcomes due to its metastatic propensity, frequent failure to …

Gefitinib is one of commonly used first-line treatment options for patients with positive EGFR
mutation in non-small cell lung cancer (NSCLC). However, most patients with gefitinib …